Primary Objectives
1. To describe baseline demographics and clinical characteristics of first-line recurrent/metastatic squamous cell carcinoma of the head and neck (1L R/M SCCHN) patients
2. To understand treatment patterns for 1L R/M SCCHN patients including their platinum-based grouping (naïve, sensitive, refractory, and ineligible)
3. To assess 1L R/M SCCHN clinical outcomes overall and by treatment (e.g., overall survival [OS], progression-free survival [PFS], duration of response [DOR])
Secondary Objectives
1. To assess patient-reported outcomes (PRO)/quality of life (QoL) in 1L R/M SCCHN patients via Functional Assessment of Cancer Therapy (FACT) instruments*
2. To report systemic therapy subsequent to 1L R/M SCCHN treatment
3. To describe Grade 3/4 treatment-related adverse events (TRAEs) in 1L R/M SCCHN patients overall, and by treatment*
4. To identify demographic and clinical predictors of treatment selection in 1L R/M SCCHN patients